07:58 AM EDT, 03/11/2025 (MT Newswires) -- Zymeworks ( ZYME ) shares slumped 46% pre-bell Tuesday, adding to Monday's losses.

Arvinas ( ARVN ) shares retreated 41% after the company and Pfizer (PFE) said their phase 3 trial of vepdegestrant for the treatment of breast cancer failed to reach statistical significance in improvement in progression free survival in the intent-to-treat population.

Evolus ( EOLS ) shares fell 36% after Monday's 6.6% loss.

Stoke Therapeutics ( STOK ) shares decreased 36% following a muted session.

Medallion Financial ( MFIN ) shares were down 32% after a 2.4% gain in the previous session.